LabCorp, the lead investor in Sera’s series C round in 2017, has returned for a $36m series D round that will drive commercialisation of the blood testing system PreTRM.
US-based prenatal diagnostics technology developer Sera Prognostics collected $36m in a series D round yesterday that featured life sciences research company Laboratory Corporation of America (LabCorp).
Investment firm Blue Ox Healthcare Partners co-led the round with two unnamed healthcare companies. The round additionally included Domain Associates, InterWest Partners, Catalyst Health Ventures and Chione.
Founded in 2008, Sera Prognostics has created a blood testing system, PreTRM, that offers a personalised, early prediction of an expectant mother’s risk of giving birth prematurely…
